Analysts have clear opinions on BBIO.
There are 3 analysts on the Wall offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $43.67 with a high forecast of $50.00 and a low forecast of $40.00. The average price target represents a 29.93% increase from the last price of $33.61.
BridgeBio Pharma, Inc. (BBIO) is followed by 3 analysts on the street.
null from rates it a .
Similarly, null of a with a target of .
The consensus on the street is Strong Buy.
What does BridgeBio Pharma, Inc.(BBIO) do ?
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
BridgeBio Pharma, Inc. (BBIO) Insider Trades
Multiple company employees have indulged in significant insider trading. BridgeBio Pharma, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
See Remarks, Turtle Cameron : S – Sale+OE(-$440,211) of BBIO in the trading session of 2020-01-08.
See Remarks Henderson Michael Thomas : S – Sale(-$131,861) of BBIO in the trading session of 2020-01-02.
See Remarks Kumar Neil : S – Sale(-$3,902,417) of BridgeBio Pharma, Inc. in the trading session of 2020-01-02.